Samedan Ltd Pharmaceutical Publishers


Advanced search

Publications European Pharmaceutical Contractor European Biopharmaceutical Review International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Innovations in Pharmaceutical Technology Subscribe Online White Papers Samedan app Pharmaceutical Directory Industry Events Calendar News and Press Releases Employment Opportunities Advertising with us Contact Us

home > ebr

PUBLICATIONS

European Biopharmaceutical Review

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising

David Hirsh

Editorial

Emma Naks

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

	Subscribe
	Current Issue
	Archives
	Media Info
	Our Clients

Featured in this issue

Biodevelopment and Manufacturing
Biomanufacturing Strategies

Keep it Flexible

Accinov’s Sylvain Peyrache and Agnes Nagy contemplate the effect biologics are having on the biopharmaceutical industry. With the recent progression of technology, new solutions are allowing companies to implement biomanufacturing strategies far more easily according to regulation requirements and project timelines.

INTELLECTUAL PROPERTY AND TECH-TRANSFER
Intellectual Property Act

Right of Way

Jasnoop Cheema at Greenaway Scott assesses the UK’s Intellectual Property Act, outlining how the latest changes hope to simplify the current patenting process and encourage growth in the life sciences sector.

Biodevelopment and Manufacturing
Cell-Based Therapeutics

Heading For Market

Stefanos Theoharis from apceth GmbH maintains that it is imperative to keep in mind the various end-goals when developing cell-based therapeutics. This will position the final product well in the marketplace of tomorrow, and deliver real benefit to patients in need.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd

Published quarterly in
January, April,
July and October

Industry Events

Clinical Trial Supply New England

10-11 March 2015, Boston, USA

We are delighted to announce the Clinical Trial Supply New Englandconference will be taking place in Boston on the 10th and 11th March 2015. Building on the growing success of this conference, the 3rd annual event will once again provide a unique platform for discussion and debate into the biggest challenges currently facing the clinical supply chain.
More info >>

All events >>

News and Press Releases

Advances and Progress in Drug Design Conference

Advances and Progress in Drug Design, 16th & 17th February 2015, Marriott Regents Park Hotel, London UK
More info >>

All releases >>

Air Transport Publications

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

All white papers >>